Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
JPMA Exec Renews Call for Simpler Drug Pricing System
Japan Pharmaceutical Manufacturers Association (JPMA) Director General Kenshi Kinoshita on December 18 again voiced concern that Japan’s NHI drug pricing system has become overly complex, reiterating the need for a fair and more straightforward framework. Speaking at a press conference,…
To read the full story
Related Article
ORGANIZATION
- FPMAJ Seeks Predictability in Price Maintenance System for Innovative Medicines
June 15, 2026
- Ease Foreign Price Adjustment Rules for New Drugs to Counter MFN Policy: FPMAJ
June 15, 2026
- Society Envisions 1 Trillion Yen in Overseas Sales for Japan’s Off-Patent Drug Sector by 2040
June 9, 2026
- Employees of 9 Pharma Firms Team Up for LGBTQ+ Inclusion
June 8, 2026
- Time Ripe for Debate on Drug Spending Macroeconomic Indexing: INES
June 3, 2026
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…